Search

Special train fare discount

Discounts of up to 75% on Trenitalia train journeys for EHA2025 delegates.

Read more

EHA-PTHiT Mini Hematology Tutorial

EHA and the Polish Society of Hematology and Transfusion (PTHiT) are happy to present the second virtual 'mini Tutorial'. This two-day meeting aims to assess and increase your knowledge of the treatment of myeloid and lymphoid diseases.

Read more

EHA Exam

An annual assessment designed to test your knowledge of the European Hematology Curriculum. EHA Exam 2025
The 9th European Hematology Exam will take place on June 12, 2025, from 13:30–16:00 (CEST).

Read more

EHA-RHS-ROHS Hematology Tutorial on Real World Challenges and Opportunities in Diagnostics and Management of Onco-hematological Patients Today

Dates: April 12-13, 2019
Location: Moscow, Russia
Chairs: P Sonneveld, I Poddubnaya, E Parovichnikova

Goal of the meeting
This 1,5 day meeting focuses on the most vital practical issues in oncohematology to teach the participants the appropriate and effective ways to use all the variety…

Read more

Meeting report | HOPE LA 2019 | Mendoza, Argentina

The first edition of the Highlights of Past EHA (HOPE) meeting in Latin America (LA) was held on October 4-5, 2019 in Mendoza, Argentina.

Read more

Turkey tutorial focused on lymphoma

The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.

Read more

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more